Now Reading: Cohance Lifesciences Reports Rs 45.19 Crore Q1 Loss
-
01
Cohance Lifesciences Reports Rs 45.19 Crore Q1 Loss
Cohance Lifesciences reported a consolidated loss of Rs 45.19 crore for the quarter ended June, against a profit of Rs 46.40 crore a year earlier. Total income fell to Rs 434.51 crore…
The Story in Brief
Cohance Lifesciences reported a consolidated loss of Rs 45.19 crore for the quarter ended June, against a profit of Rs 46.40 crore a year earlier. Total income fell to Rs 434.51 crore from Rs 563.48 crore, with the company citing shipment timing, weaker agrochemical and formulations revenue, and lower CDMO contribution. Gross margin narrowed to 71.5% from 73%.
The Hindu reports that a US FDA inspection of the company’s Hyderabad facility produced five observations, none linked to data integrity. Cohance said it is preparing corrective actions. NDTV Profit reports that the shares rose more than 2%, as investors focused on the inspection outcome despite the weak results. The company expects improvement from the second quarter and year-on-year growth in the second half.
The Indian Opinion
The easy story is either that the FDA outcome clears Cohance or that the quarterly loss signals a broken business. Neither follows from the available facts. Five observations still require corrective action, while management’s recovery forecast depends on shipments, orders and a late-stage pipeline. Investors should watch second-half revenue and EBITDA, not just a one-day share move. The next results will show whether the promised return to growth has begun.
Sources (2): ndtvprofit.com, thehindu.com
This story was synthesised by AI from the 2 sources linked above.
Updated: this story now draws on 2 sources.
